Bryleos

Early clinical stage therapeutics company developing BRY101, a metabolic modulator engineered to increase intracellular NAD, impacting mitochondrial dysfunction, neuroinflammation and oxidative stress. BRY101 impacts multiple pathways simultaneously, breaking away from the traditional single-target... Read more